Show simple item record

dc.contributor.authorFassan, M
dc.contributor.authorVianello, L
dc.contributor.authorSacchi, D
dc.contributor.authorFanelli, GN
dc.contributor.authorMunari, G
dc.contributor.authorScarpa, M
dc.contributor.authorCappellesso, R
dc.contributor.authorLoupakis, F
dc.contributor.authorLanza, C
dc.contributor.authorSalmaso, R
dc.contributor.authorMescoli, C
dc.contributor.authorValeri, N
dc.contributor.authorAgostini, M
dc.contributor.authorD'Angelo, E
dc.contributor.authorLonardi, S
dc.contributor.authorPucciarelli, S
dc.contributor.authorVeronese, N
dc.contributor.authorLuchini, C
dc.contributor.authorRugge, M
dc.date.accessioned2019-02-20T07:44:51Z
dc.date.issued2018-09-06
dc.identifier.citationCancer cell international, 2018, 18 pp. 131 - ?
dc.identifier.issn1475-2867
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3058
dc.identifier.eissn1475-2867
dc.identifier.doi10.1186/s12935-018-0634-8
dc.description.abstractBACKGROUND: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). METHODS: A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the primary CRC, an ENE-negative and an ENE-positive metastatic LN). Samples (n = 66) were analysed by immunohistochemistry for PD-L1, CD4, CD8, CD68 and CD80. Fifteen out of twenty-two cases were further profiled through a hotspot multigene mutational custom panel, including 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 genes. RESULTS: A significantly higher percentage of CD4-, CD8- and CD68-positive cells was observed at the invasive front of both CRCs and in ENE in contrast with what observed at the core of both CRCs and their matched nodal metastases. ENE was also characterized by a significantly higher number of CD80-positive cells. No significant difference was observed in PD-L1 distribution among the different specimens. Fourteen out of 15 CRCs (93%) showed at least a driver mutation. The most frequently mutated gene was TP53 (n = 8 tumors), followed by APC (n = 6), BRAF (n = 4), KRAS, NRAS and PIK3CA (n = 2). In 11 out of 15 CRCs (73%) the mutational profiling of the primary tumor was consistent with what obtained from the two matched LNs. CONCLUSIONS: A heterogeneous intratumor immune-microenvironment has been observed in ENE-positive CRCs, which are characterized by an increased leukocytic infiltration at the ENE invasive front.
dc.formatElectronic-eCollection
dc.format.extent131 - ?
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleAssessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases.
dc.typeJournal Article
dcterms.dateAccepted2018-09-03
rioxxterms.versionofrecord10.1186/s12935-018-0634-8
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer cell international
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
icr.researchteamGastrointestinal Cancer Biology and Genomics
dc.contributor.icrauthorValeri, Nicola


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0